By Finance Pulse in KeyInfo —

Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer

Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.

A visually compelling image of a DNA strand symbolizing gene therapy, with soft blue and green hues
Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer

Sangamo will regain rights to giroctocogene fitelparvovec, despite successful Phase 3 trials reported by Pfizer in July.

Source